Crossmark

Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review

Crossref DOI link: https://doi.org/10.1007/s40122-021-00264-x

Published Online: 2021-04-21

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Blumenfeld, Andrew M.

Frishberg, Benjamin M.

Schim, Jack D.

Iannone, Ashley

Schneider, Gary

Yedigarova, Larisa

Manack Adams, Aubrey
Funding

Funding for this research was provided by:

AbbVie
License Information

Text and Data Mining valid from 2021-04-21

Version of Record valid from 2021-04-21
More Information

Article History

Received: 18 December 2020

Accepted: 1 April 2021

First Online: 21 April 2021

Change Date: 25 October 2021

Change Type: Update

Change Details: A peer-reviewed video abstract was retrospectively added to this publication.

Document is current

Any future updates will be listed below